Advisory Alpha’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.68M | Buy |
7,238
+1,047
| +17% | +$1.07M | 0.21% | 66 |
|
|
2026
Q1 | $5.7M | Buy |
6,191
+151
| +3% | +$153K | 0.16% | 76 |
|
|
2025
Q4 | $6.49M | Buy |
6,040
+790
| +15% | +$755K | 0.18% | 68 |
|
|
2025
Q3 | $4.31M | Buy |
5,250
+605
| +13% | +$450K | 0.12% | 78 |
|
|
2025
Q2 | $3.62M | Buy |
4,645
+477
| +11% | +$371K | 0.11% | 87 |
|
|
2025
Q1 | $3.44M | Buy |
4,168
+417
| +11% | +$347K | 0.12% | 84 |
|
|
2024
Q4 | $2.9M | Buy |
3,751
+133
| +4% | +$110K | 0.1% | 83 |
|
|
2024
Q3 | $3.21M | Buy |
3,618
+410
| +13% | +$369K | 0.11% | 81 |
|
|
2024
Q2 | $2.9M | Buy |
3,208
+195
| +6% | +$156K | 0.11% | 87 |
|
|
2024
Q1 | $2.34M | Buy |
3,013
+1,401
| +87% | +$997K | 0.1% | 100 |
|
|
2023
Q4 | $940K | Buy |
1,612
+818
| +103% | +$477K | 0.04% | 148 |
|
|
2023
Q3 | $427K | Sell |
794
-9,172
| -92% | -$4.73M | 0.02% | 205 |
|
|
2023
Q2 | $4.67M | Buy |
9,966
+35
| +0.4% | +$14.7K | 0.24% | 63 |
|
|
2023
Q1 | $3.41M | Buy |
9,931
+78
| +0.8% | +$26.3K | 0.22% | 58 |
|
|
2022
Q4 | $3.6M | Buy |
9,853
+122
| +1% | +$43.3K | 0.26% | 49 |
|
|
2022
Q3 | $3.15M | Sell |
9,731
-33
| -0.3% | -$10.5K | 0.24% | 57 |
|
|
2022
Q2 | $3.17M | Sell |
9,764
-61
| -0.6% | -$18.3K | 0.24% | 50 |
|
|
2022
Q1 | $2.81M | Buy |
9,825
+92
| +0.9% | +$23.7K | 0.18% | 58 |
|
|
2021
Q4 | $2.69M | Buy |
9,733
+79
| +0.8% | +$20K | 0.16% | 66 |
|
|
2021
Q3 | $2.23M | Buy |
9,654
+24
| +0.2% | +$5.92K | 0.15% | 75 |
|
|
2021
Q2 | $2.21M | Buy |
9,630
+4
| +0% | +$803 | 0.18% | 68 |
|
|
2021
Q1 | $1.8M | Sell |
9,626
-65
| -0.7% | -$12.7K | 0.18% | 61 |
|
|
2020
Q4 | $1.64M | Buy |
9,691
+63
| +0.7% | +$9.41K | 0.33% | 26 |
|
|
2020
Q3 | $1.43M | Sell |
9,628
-15
| -0.2% | -$2.32K | 0.31% | 27 |
|
|
2020
Q2 | $1.47M | Buy |
9,643
+8,303
| +620% | +$1.27M | 0.33% | 30 |
|
|
2020
Q1 | $214K | Buy |
1,340
+141
| +12% | +$19.4K | 0.06% | 95 |
|
|
2019
Q4 | $167K | Sell |
1,199
-43
| -3% | -$4.98K | 0.04% | 151 |
|
|
2019
Q3 | $133K | Buy |
+1,242
| New | +$138K | 0.04% | 149 |
|
|
2019
Q2 | – | Sell |
-1,214
| Closed | -$141K | – | 414 |
|
|
2019
Q1 | $141K | Buy |
+1,214
| New | +$148K | 0.05% | 136 |
|
Other funds holding LLY
Advisory Alpha's LLY Position: Q2 2026 in Review
Advisory Alpha increased its Eli Lilly (LLY) stake by 17% in Q2 2026, buying an estimated $1.07M and bringing the position to 7,238 shares worth $8.68M. The position accounts for 0.21% of the portfolio, ranked #66.
Advisory Alpha first reported a position in LLY in Q1 2019 and has held it in 29 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Advisory Alpha held 7,238 shares of Eli Lilly worth $8.68M as of Q2 2026.
- Advisory Alpha bought 1,047 Eli Lilly shares in Q2 2026, an estimated $1.07M.
- Eli Lilly made up 0.21% of Advisory Alpha's portfolio in Q2 2026, its #66 holding.
- Advisory Alpha first reported a position in Eli Lilly in Q1 2019 and has held it in 29 quarters since.
- 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Advisory Alpha's 13F filing for Q2 2026, filed 11 Aug 2026.